XML 47 R36.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Acquisitions, Divestitures, Research Collaborations and Licensing Agreements - Narrative (Details)
$ in Millions
 1 Months Ended 3 Months Ended 6 Months Ended
Jun. 02, 2021
Jul. 31, 2024
USD ($)
aqua_facility
candidate
Mar. 31, 2024
USD ($)
Jun. 30, 2023
USD ($)
Jan. 31, 2023
USD ($)
Sep. 30, 2024
USD ($)
Jun. 30, 2024
USD ($)
jurisdiction
Jun. 30, 2023
USD ($)
Jun. 30, 2024
USD ($)
jurisdiction
Jun. 30, 2023
USD ($)
Dec. 31, 2023
USD ($)
Oct. 31, 2023
USD ($)
candidate
Feb. 28, 2023
candidate
Business Acquisition [Line Items]                          
Research and development             $ 3,500 $ 13,321 $ 7,492 $ 17,597      
Sales             16,112 15,035 31,887 29,522      
Cost of sales             3,745 4,024 7,285 7,951      
Other current assets             8,740   8,740   $ 8,368    
Accrued and other current liabilities             14,712   14,712   15,766    
Related Party                          
Business Acquisition [Line Items]                          
Other current assets             557   557   632    
Accrued and other current liabilities             102   102   $ 598    
Manufacturing and Supply Agreements | Related Party                          
Business Acquisition [Line Items]                          
Sales             93 96 201 191      
Cost of sales             $ 92 101 $ 202 208      
Minimum | Manufacturing and Supply Agreements | Related Party                          
Business Acquisition [Line Items]                          
Period of continuing involvement after disposal 4 years                        
Maximum | Manufacturing and Supply Agreements | Related Party                          
Business Acquisition [Line Items]                          
Period of continuing involvement after disposal 10 years                        
Discontinued Operations, Disposed of by Means Other than Sale, Spinoff | Organon & Co.                          
Business Acquisition [Line Items]                          
Number of jurisdictions remaining | jurisdiction             1   1        
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement                          
Business Acquisition [Line Items]                          
Number of antibody drug conjugates obtained right and obligations | candidate                         7
Upfront payment made to collaborative partner       $ 175       175   175      
Number of antibody drug conjugates terminated with collaborative partner | candidate                       2  
Eligible future contingent development-related payments (up to)                       $ 540  
Eligible future contingent regulatory milestone payments (up to)                       1,500  
Eligible future contingent sales-based milestone payments (up to)                       $ 3,100  
Stock investment in counterparty         $ 100                
Harpoon Therapeutics, Inc.                          
Business Acquisition [Line Items]                          
Consideration transferred, asset acquisition     $ 765                    
Research and development                 $ 656        
Asset acquisition, transaction costs     56                    
Net assets acquired     $ 165                    
Prometheus Biosciences, Inc.                          
Business Acquisition [Line Items]                          
Consideration transferred, asset acquisition       11,000                  
Research and development               $ 10,200   10,200      
Net assets acquired       877                  
Consideration transferred, to settle share-based equity awards       1,200                  
Consideration transferred, to settle equity awards, unvested       700                  
Cash recorded for asset acquisition       368                  
Investments recorded for asset acquisition       296                  
Deferred tax assets recorded for asset acquisition       218                  
Other net liabilities recorded for asset acquisition       $ 5                  
Imago Bio Sciences, Inc.                          
Business Acquisition [Line Items]                          
Consideration transferred, asset acquisition         1,350                
Research and development                   $ 1,200      
Asset acquisition, transaction costs         60                
Net assets acquired         $ 219                
Forecast | Eyebiotech Limited                          
Business Acquisition [Line Items]                          
Research and development           $ 1,300              
Subsequent Event | Orion                          
Business Acquisition [Line Items]                          
Eligible future contingent development-related payments (up to)   $ 30                      
Eligible future contingent regulatory milestone payments (up to)   625                      
Eligible future contingent sales-based milestone payments (up to)   $ 975                      
Subsequent Event | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement                          
Business Acquisition [Line Items]                          
Number of exercised license option antibody drug conjugates | candidate   1                      
Number of licensed antibody drug conjugates | candidate   3                      
Number of unexercised license option antibody drug conjugates | candidate   1                      
Payment resulting from the license option exercise   $ 38                      
Subsequent Event | Eyebiotech Limited                          
Business Acquisition [Line Items]                          
Consideration transferred, asset acquisition   1,300                      
Potential developmental, regulatory and commercial milestone payments   1,700                      
Elanco Animal Health Incorporated Aqua Business | Subsequent Event                          
Business Acquisition [Line Items]                          
Payment to acquire business   $ 1,300                      
Aqua manufacturing facilities | aqua_facility   2